Cytomegalovirus-vectored COVID-19 vaccines elicit neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.2) in mice

ABSTRACT Viral vector vaccine represents one of the important research directions of novel vaccines. Viral vectors can efficiently deliver foreign genes and drive robust transgene expression in vivo. Generally, viral vector vaccines can achieve high immunogenicity and rapid response to a new pandemi...

Full description

Bibliographic Details
Published in:	Microbiology Spectrum
Main Authors:	Jian Liu, Dabbu Kumar Jaijyan, Yanling Chen, Changcan Feng, Shaomin Yang, Zhenglong Xu, Nichun Zhan, Congming Hong, Shuxuan Li, Tong Cheng, Hua Zhu
Format:	Article
Language:	English
Published:	American Society for Microbiology 2023-12-01
Subjects:	cytomegalovirus viral vector-based vaccine immunogenicity evaluation SARS-CoV-2 variant of concern
Online Access:	https://journals.asm.org/doi/10.1128/spectrum.02463-23

Similar Items

MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses
by: Patricia Pérez, et al.
Published: (2024-08-01)

Exploring the Potential of Cytomegalovirus-Based Vectors: A Review
by: Janine Zeng, et al.
Published: (2023-10-01)

Serum neutralizing capacity and T-cell response against the omicron BA.1 variant in seropositive children and their parents one year after SARS-CoV-2 infection
by: Alina Seidel, et al.
Published: (2023-03-01)

Iota-Carrageenan Inhibits Replication of the SARS-CoV-2 Variants of Concern Omicron BA.1, BA.2 and BA.5
by: Christian Setz, et al.
Published: (2023-07-01)

Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections
by: Iris Medits, et al.
Published: (2022-07-01)

Molecular mechanisms responsible for SARS-CoV-2 antibody waning and vaccine escape in Omicron sublineages BA.4 and BA.5
by: Benjamin Hewins, et al.
Published: (2022-07-01)

Comparative Analysis of Vaccine-Induced Neutralizing Antibodies against the Alpha, Beta, Delta, and Omicron Variants of SARS-CoV-2
by: Philipp Girl, et al.
Published: (2024-05-01)

The Omicron Lineages BA.1 and BA.2 (<i>Betacoronavirus</i> SARS-CoV-2) Have Repeatedly Entered Brazil through a Single Dispersal Hub
by: Alessandra P. Lamarca, et al.
Published: (2023-03-01)

COVID-19 vaccine induced poor neutralization titers for SARS-CoV-2 omicron variants in maternal and cord blood
by: Sakthivel Govindaraj, et al.
Published: (2023-07-01)

Broad-spectrum humanized monoclonal neutralizing antibody against SARS-CoV-2 variants, including the Omicron variant
by: Kun Wen, et al.
Published: (2023-08-01)

Analytical Sensitivity of Eight Different SARS-CoV-2 Antigen-Detecting Rapid Tests for Omicron-BA.1 Variant
by: Meriem Bekliz, et al.
Published: (2022-08-01)

Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination
by: Nuchjira Takheaw, et al.
Published: (2022-05-01)

Sequential viral introductions and spread of BA.1 across Pakistan provinces during the Omicron wave
by: Ali Raza Bukhari, et al.
Published: (2023-08-01)

Clinical and humoral immune response characterization of SARS-CoV-2 Omicron BA.2.38 infection in pediatric patients
by: Yu Liu, et al.
Published: (2023-07-01)

The T Cell Epitope Landscape of SARS-CoV-2 Variants of Concern
by: Simen Tennøe, et al.
Published: (2022-07-01)

The First Identification in Italy of SARS-CoV-2 Omicron BA.4 Harboring KSF141_del: A Genomic Comparison with Omicron Sub-Variants
by: Cinzia Peronace, et al.
Published: (2022-07-01)

Circular RNAs Represent a Novel Class of Human Cytomegalovirus Transcripts
by: Shaomin Yang, et al.
Published: (2022-06-01)

Surveillance for SARS-CoV-2 Variants of Concern and Initial Detection of Omicron using RT-PCR in the Kurdistan region of Iraq
by: Dlshad Abdullah Hasan, et al.
Published: (2023-07-01)

The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far
by: Vivek P. Chavda, et al.
Published: (2022-11-01)

Development and Validation of an In-House Real-Time Reverse-Transcriptase Polymerase Chain Reaction Assay for SARS-CoV-2 Omicron Lineage Subtyping between BA.1 and BA.2
by: David Pham, et al.
Published: (2022-08-01)

Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study
by: Shinya Murata, et al.
Published: (2023-03-01)

Reinfection rate and disease severity of the BA.5 Omicron SARS-CoV-2 lineage compared to previously circulating variants of concern in the Canary Islands (Spain)
by: Laura Ciuffreda, et al.
Published: (2023-12-01)

Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination
by: Yuxin Chen, et al.
Published: (2021-01-01)

Genomic Perspectives on the Emerging SARS-CoV-2 Omicron Variant
by: Wentai Ma, et al.
Published: (2022-02-01)

An Oral <i>Salmonella</i>-Based Vaccine Expressing Viral M43 Protein Elicits Effective Immunity Against Murine Cytomegalovirus in Mice
by: Yujun Liu, et al.
Published: (2025-09-01)

Sequencing and mutations analysis of the first recorded SARS-CoV-2 Omicron variant during the fourth wave of pandemic in Iraq
by: Jivan Qasim Ahmed, et al.
Published: (2022-09-01)

From Alpha to Omicron: How Different Variants of Concern of the SARS-Coronavirus-2 Impacted the World
by: Mickensone Andre, et al.
Published: (2023-09-01)

The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV)
by: Adewunmi Akingbola, et al.
Published: (2025-12-01)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
by: Jinyoung Yang, et al.
Published: (2023-03-01)

Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naïve and Convalescent BNT162b2 Recipients
by: Jia Fu, et al.
Published: (2022-11-01)

A promising endeavor against human cytomegalovirus: Predominant epitopes-based recombinant subunit vaccine RHEcIE1/pp65/pp150
by: Zonghui Li, et al.
Published: (2025-12-01)

Epidemiologic Features and Containment of SARS-CoV-2 Omicron Variant
by: WU Yu, LIU Jue, LIU Min, LIANG Wannian
Published: (2022-01-01)

Influence of Distinct Maternal Cytomegalovirus-Specific Neutralizing and Fc Receptor-Binding Responses on Congenital Cytomegalovirus Transmission in HIV-Exposed Neonates
by: Itzayana G. Miller, et al.
Published: (2025-02-01)

Immune Evasion by the Highly Mutated SARS-CoV-2 Omicron Variant
by: Mengist HM, et al.
Published: (2022-07-01)

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
by: I-Jung Lee, et al.
Published: (2022-07-01)

INFLUENCE OF CYTOMEGALOVIRUS PERSISTENCE UPON CLINICAL COURSE OF BRONCHIAL ASTHMA (BA) IN CHILDREN
by: Е. N. Suprun, et al.
Published: (2014-07-01)

Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
by: Hao Zhou, et al.
Published: (2022-06-01)

Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan
by: Tomoyuki Kakugawa, et al.
Published: (2023-08-01)

Resurgence of SARS-CoV-2 Delta after Omicron variant superinfection in an immunocompromised pediatric patient
by: Arghavan Alisoltani, et al.
Published: (2023-10-01)

SARS-CoV-2 before and after Omicron: two different viruses and two different diseases?
by: Renata Gili, et al.
Published: (2023-04-01)